

Hongfu Cai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4752578/publications.pdf>

Version: 2024-02-01

5
papers

77
citations

1937685

4
h-index

2053705

5
g-index

5
all docs

5
docs citations

5
times ranked

70
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China. <i>Clinical Therapeutics</i> , 2019, 41, 280-290.	2.5	37
2	First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 602185.	2.8	22
3	Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2951-2959.	1.3	9
4	Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 4263-4270.	1.9	6
5	Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1301-1309.	1.4	3